NCT01111825 2018-09-26
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.